Cystic Fibrosis Drugs Market Outlook:
Cystic Fibrosis Drugs Market size was valued at USD 10.3 billion in 2024 and is projected to reach USD 57.7 billion by the end of 2037, rising at a CAGR of 14.2% during the forecast period, i.e., 2025–2037. In 2025, the industry size of cystic fibrosis drugs is assessed at USD 11.8 billion.
According to the Cystic Fibrosis Foundation, in 2025, the number of patients with cystic fibrosis is projected to remain 20,500 in Europe and 30,100 in the U.S. The cystic fibrosis therapeutics include the combination of APIs such as elexacaftor, ivacaftor, etc. The study was conducted under the Drug Supply Chain Security Act (DSCSA), showed that sustained import volumes consist of marginal price variance, showcasing stable pricing for the core active ingredients. Also, the Cystic Fibrosis-focused research, development, and deployment investment has reached USD 243.2 million in 2023.
Additionally, the drug market for Cystic Fibrosis depends on a robust and traceable supply chain consisting of finished goods and remarkable funding for the RDD. The advent of effective drugs such as Orkambi, Kalydeco, etc. has revolutionized the treatment, enhancing the life expectancy and quality of life. Various trailblazing companies are conducting trials for fabricating next-generation modulators. The market is also getting support from the increasing efforts of orphan drug incentives, further bolstering the market growth during the forecasted period.
